AGN 2.99% 86.0¢ argenica therapeutics limited

The stroke clinical program is probably too far ahead of HIE for...

  1. 1,430 Posts.
    lightbulb Created with Sketch. 482
    The stroke clinical program is probably too far ahead of HIE for HIE to be approved first.

    So very unlikely to be awarded a priority review voucher.

    Still great endorsement/validation from the FDA for the pre-clinical work done to-date.
 
watchlist Created with Sketch. Add AGN (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.